Giant cell tumour of tendon sheath – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Giant cell tumour of tendon sheath – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor https://clinicaltrials.eu/trial/study-on-emactuzumab-for-patients-with-tenosynovial-giant-cell-tumor/ Wed, 29 Apr 2026 15:00:28 +0000 https://clinicaltrials.eu/trial/study-on-emactuzumab-for-patients-with-tenosynovial-giant-cell-tumor/ This study focuses on Tenosynovial Giant Cell Tumour (TGCT), which is a rare type of growth that affects the tissue lining around joints and tendons. The study will test a medication called emactuzumab, which will be given through intravenous infusion, comparing it with placebo to determine if it can effectively treat this condition.

The purpose of this research is to evaluate how well emactuzumab works in treating TGCT by measuring the rate at which tumors respond to treatment within 6 months of starting therapy. The medication will be given as a solution that is administered directly into a vein. Some participants will receive emactuzumab, while others will receive placebo.

During the study, participants will first take part in a 6-month phase where they will receive either emactuzumab or placebo without knowing which treatment they are getting. The study will track various aspects of participants’ health, including their pain levels, joint stiffness, and physical function. Doctors will use magnetic resonance imaging (MRI) to monitor changes in the tumors. The total treatment period may last up to 10 months, and participants will be monitored for any effects of the treatment.

]]> Study on the Safety and Effectiveness of ABSK021 for Patients with Tenosynovial Giant Cell Tumor https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-absk021-for-patients-with-tenosynovial-giant-cell-tumor/ Wed, 29 Apr 2026 14:27:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-absk021-for-patients-with-tenosynovial-giant-cell-tumor/ This clinical trial is focused on studying a condition known as Tenosynovial Giant Cell Tumor (TGCT). This is a type of tumor that affects the joints and can cause pain and stiffness. The study is testing a new treatment called ABSK021, which is taken as a capsule. The purpose of the study is to determine if ABSK021 is safe and effective in treating TGCT.

Participants in the study will be randomly assigned to receive either the ABSK021 treatment or a placebo. The study will last for up to 48 weeks, during which participants will take the medication and attend regular check-ups. These check-ups will help researchers monitor the effects of the treatment on the tumor and any changes in symptoms like joint movement, stiffness, and pain.

The study aims to see how well the treatment works by measuring the size of the tumor and assessing improvements in joint function and quality of life. Participants will be closely monitored to ensure their safety throughout the study. The results will help determine if ABSK021 can be a beneficial treatment option for people with Tenosynovial Giant Cell Tumor.

]]>